9.47 USD
▲+0.18+3.05%
盘后 9.22 +0.33%
2026-08-03
市值
$840.69M
市盈率
—
EPS
-3.35
股息率
—
52 周区间
5.45 – 12.49
成交量
1.01M
Beta
0.35
目标价
31.17
52W 低 5.4552W 高 12.49
价格走势
公司简介
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional n...